Efficacy and safety of laparoscopic vs open gastrectomy after neoadjuvant therapy for locally advanced gastric cancer

Table 1 Baseline characteristics of the two groups, n (%)

Variable	LG group (n = 38)	OG group (n = 38)	P value
Age (yr)	59.3 ± 9.8	60.5 ± 10.2	0.59
Sex-male	24 (63.2)	26 (68.4)	0.71
Sex-female	14 (36.8)	12 (31.6)
BMI (kg/m)2	23.4 ± 3.2	22.9 ± 2.9	0.48
ECOG PS-0	28 (73.7)	29 (76.3)	0.86
ECOG PS-1	10 (26.3)	9 (23.7)
Comorbidities-yes	14 (36.8)	16 (42.1)	0.67
Comorbidities-no	24 (63.2)	22 (57.9)
Tumor location-upper third	10 (26.3)	12 (31.6)	0.75
Tumor location-middle third	14 (36.8)	13 (34.2)
Tumor location-lower third	14 (36.8)	13 (34.2)
Tumor size (cm)	5.2 ± 1.8	5.4 ± 2.1	0.66
Clinical stage1-II	14 (36.8)	15 (39.5)	0.82
Clinical stage1-III	24 (63.2)
Pathological response-complete2	4 (10.5)	3 (7.9)	0.69
Pathological response-partial2	18 (47.4)	19 (50.0)
Pathological response-stable2	12 (31.6)	11 (28.9)
Pathological response-progressive2	4 (10.5)	5 (13.2)
Type of gastrectomy-total2	20 (52.6)	21 (55.3)	0.88
Type of gastrectomy-subtotal2	18 (47.4)	17 (44.7)

¹According to the 8^th edition of the American Joint Committee on Cancer staging system.

²According to the RECIST version 1.1.

LG: Laparoscopic gastrectomy; OG: Open gastrectomy; BMI: Body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status.